Side-by-side comparison of AI visibility scores, market position, and capabilities
Software subscription management platform with virtual cards and spend controls; London UK; raised $20M+; gives finance teams control over SaaS purchases company-wide.
Cledara is a software subscription management platform headquartered in London, UK, that combines SaaS visibility with virtual card-based spend controls to give finance and operations teams oversight of every software subscription in their organization. The company raised over $20 million in funding and has built strong traction among technology companies and startups in Europe and North America.\n\nThe platform's virtual card model is central to its approach: each SaaS subscription is assigned its own Cledara virtual card, which can be managed, paused, or cancelled independently. This creates a natural control layer over software spending without requiring employees to go through a lengthy procurement approval process for every tool purchase.\n\nCledara also provides automated subscription tracking, renewal alerts, usage analytics, and accounting integrations that help finance teams maintain an accurate and current view of software spend. By combining the control mechanism (virtual cards) with the intelligence layer (analytics and renewals management), Cledara creates a practical solution for companies at the stage where software sprawl begins to create budget visibility problems but full enterprise procurement systems are not yet warranted.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.